1. Home
  2. AKBA vs NTGR Comparison

AKBA vs NTGR Comparison

Compare AKBA & NTGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AKBA
  • NTGR
  • Stock Information
  • Founded
  • AKBA 2007
  • NTGR 1996
  • Country
  • AKBA United States
  • NTGR United States
  • Employees
  • AKBA N/A
  • NTGR N/A
  • Industry
  • AKBA Biotechnology: Pharmaceutical Preparations
  • NTGR Telecommunications Equipment
  • Sector
  • AKBA Health Care
  • NTGR Utilities
  • Exchange
  • AKBA Nasdaq
  • NTGR Nasdaq
  • Market Cap
  • AKBA 958.6M
  • NTGR 787.2M
  • IPO Year
  • AKBA 2014
  • NTGR N/A
  • Fundamental
  • Price
  • AKBA $3.69
  • NTGR $28.53
  • Analyst Decision
  • AKBA Strong Buy
  • NTGR Buy
  • Analyst Count
  • AKBA 5
  • NTGR 1
  • Target Price
  • AKBA $6.90
  • NTGR $29.00
  • AVG Volume (30 Days)
  • AKBA 6.6M
  • NTGR 440.6K
  • Earning Date
  • AKBA 08-07-2025
  • NTGR 07-30-2025
  • Dividend Yield
  • AKBA N/A
  • NTGR N/A
  • EPS Growth
  • AKBA N/A
  • NTGR N/A
  • EPS
  • AKBA N/A
  • NTGR 0.85
  • Revenue
  • AKBA $184,909,000.00
  • NTGR $671,233,000.00
  • Revenue This Year
  • AKBA $26.88
  • NTGR $4.48
  • Revenue Next Year
  • AKBA $44.34
  • NTGR $5.04
  • P/E Ratio
  • AKBA N/A
  • NTGR $33.69
  • Revenue Growth
  • AKBA N/A
  • NTGR N/A
  • 52 Week Low
  • AKBA $0.80
  • NTGR $13.96
  • 52 Week High
  • AKBA $4.08
  • NTGR $31.55
  • Technical
  • Relative Strength Index (RSI)
  • AKBA 63.96
  • NTGR 50.55
  • Support Level
  • AKBA $3.56
  • NTGR $26.35
  • Resistance Level
  • AKBA $3.87
  • NTGR $27.68
  • Average True Range (ATR)
  • AKBA 0.22
  • NTGR 0.92
  • MACD
  • AKBA -0.04
  • NTGR -0.24
  • Stochastic Oscillator
  • AKBA 36.53
  • NTGR 41.96

About AKBA Akebia Therapeutics Inc.

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.

About NTGR NETGEAR Inc.

Netgear Inc provider of networking technologies for businesses, homes, and service providers. It delivers a wide range of intelligent solutions designed to unleash the full potential of connectivity. The group has two segments: NETGEAR for Business and Connected Home which offers reliable, easy-to-use, high-performance networking solutions, including switches, routers, access points, software, and AV over IP technologies, tailored to meet the diverse needs of organizations of all sizes. The Connected Home segment offers connectivity, powerful performance, and enhanced security features right out of the box, designed to help keep families safe online, and Others. It conduct business across three geographic territories: Americas; Europe, Middle East and Africa; and Asia Pacific.

Share on Social Networks: